^
    Back
    Association details:
    Biomarker:AURKA overexpression
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Mol Cell Oncol
    Title:

    Aurora A and Mcl-1: new potential treatment targets in antiestrogen-resistant breast cancer

    Published date:
    12/17/2021
    Excerpt:
    We analyzed the expression of Aurora A in ERα positive primary breast tumors from 244 patients, who had received adjuvant tamoxifen therapy, and our data revealed a significant association between higher Aurora A expression and shorter time to recurrence and death.
    DOI:
    10.1080/23723556.2014.998898
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Oncogene
    Title:

    Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERa in breast cancer

    Published date:
    10/16/2014
    Excerpt:
    Aurora-A interacts with and phosphorylates ERα on serine-167 and -305, leading to increase in ERα DNA-binding and transcriptional activity. Elevated levels of Aurora-A are significantly associated with disease-free survival in ERα-positive but not ERα-negative breast cancers. These data suggest that Aurora-A has a pivotal role in tamoxifen resistance and ERα is a bona fide substrate of Aurora-A.
    DOI:
    10.1038/onc.2013.444